- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT04489797
A Study to Evaluate Effects of Proton-pump Inhibitor on Acalabrutinib Capsule When Administered Orally With COCA-COLA in Healthy Participants
A Phase I, Open-label, Randomized, Single-dose Study of Acalabrutinib in Healthy Subjects to Evaluate the Effect of Proton-pump Inhibitor (Rabeprazole) on Acalabrutinib Capsule When Administered Orally With COCA-COLA
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
Study Type
Enrollment (Actual)
Phase
- Phase 1
Contacts and Locations
Study Locations
-
-
California
-
Anaheim, California, United States, 92801
- Research Site
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Capable of giving signed informed consent.
- Male participants and their female partners/spouses must adhere to the contraception methods.
Female participants must have a negative pregnancy test at screening, must not be lactating, and must be of non-childbearing potential, confirmed at screening by fulfilling one of the following criteria:
- Postmenopausal defined as amenorrhea for at least 12 months following cessation of all exogenous hormonal treatments and follicle stimulating hormone levels in the postmenopausal range.
- Documentation of irreversible surgical sterilization by hysterectomy, bilateral oophorectomy, or bilateral salpingectomy but not bilateral tubal ligation.
- Have a body mass index between 18.5 and 30 kg/m^2, inclusive, and weigh at least 50 kg and no more than 100 kg, inclusive, at screening.
- Understands the study procedures in the informed consent form and willing and able to comply with the protocol.
Exclusion Criteria:
- History or presence of any clinically significant disease (including active coronavirus disease 2019 infection).
- History or presence of gastrointestinal, hepatic or renal disease, or any other condition known to interfere with absorption, distribution, metabolism, or excretion of drugs.
- Any clinically significant illness, medical/surgical procedure, or trauma within 30 days of the first administration of investigational medicinal product (IMP).
Any clinically significant abnormalities in hematology, coagulation, clinical chemistry, or urinalysis results, at screening defined as:
- Hemoglobin less than lower limit of normal.
- Serum alanine aminotransferase, aspartate aminotransferase, alkaline phosphatase or serum bilirubin (total and direct) > 1.5 upper limit of normal.
- Any clinically significant abnormal findings in vital signs at screening (eg, systolic blood pressure [BP] < 90 mmHg or ≥ 140 mmHg; diastolic BP < 50 mmHg or ≥ 90 mmHg; pulse < 50 or > 90 bpm).
- Any clinically significant abnormalities on standard 12-lead electrocardiogram at screening.
- Any positive result on screening for serum Hepatitis B surface antigen, hepatitis B, hepatitis C, and Human immunodeficiency virus antibody.
- Has received a new chemical entity within 90 days of the first administration of IMP in this study. The period of exclusion begins 90 days after the final dose or 30 days after the last visit whichever is the longest.
- Plasma donation within 30 days of screening or any blood donation/loss more than 500 mL during the 90 days prior to screening.
- History of severe allergy/hypersensitivity or ongoing allergy/hypersensitivity, or history of hypersensitivity to drugs with a similar chemical structure or class to acalabrutinib or rabeprazole.
- Current smokers or those who have smoked or used nicotine products within the 90 days prior to screening.
- Positive screen for drugs of abuse or cotinine at screening.
- Treatment with a strong cytochrome P450 3A (CYP3A) inhibitor (within 14 days before first administration of IMP) or strong CYP3A inducer (within 28 days before first administration of IMP).
- Use of any prescribed or non-prescribed medication including antacids, analgesics (other than paracetamol/acetaminophen), herbal remedies, megadose vitamins (intake of 20 to 600 times the recommended daily dose) and minerals during the 14 days prior to the first administration of IMP or longer if the medication has a long half-life. Hormonal replacement therapy will not be allowed.
- Known or suspected history of alcohol or drug abuse, or excessive intake of alcohol.
- Excessive intake of caffeine-containing drinks or food or would likely be unable to refrain from the use of caffeine-containing beverages during in-house stay at the Clinical Unit.
- Involvement of any AstraZeneca, Acerta Pharma, Parexel or study site employee or their close relatives.
- Judgment by the Investigator that the participant should not participate in the study if they have any ongoing or recent (ie, during the screening period) minor medical complaints that may interfere with the interpretation of study data or are considered unlikely to comply with study procedures, restrictions, and requirements.
- Participants who cannot communicate reliably with the Investigator.
- Vulnerable participants, eg, kept in detention, protected adults under guardianship, trusteeship, or committed to an institution by governmental or juridical order.
- Inability to swallow acalabrutinib capsules.
- Evidence of ongoing systemic bacterial, fungal, or viral infection (including upper respiratory tract infections). Note: Participants with localized cutaneous fungal infections are eligible.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Arm A
Participants will receive single oral dose of acalabrutinib capsule with 100 mL of water.
|
Participants will receive single oral dose of acalabrutinib on day 1 as per the arms they are randomized.
|
Experimental: Arm B
Participants will receive single oral dose of acalabrutinib capsule taken with 100 mL of COCA-COLA along with 20 mg rabeprazole.
|
Participants will receive single oral dose of acalabrutinib on day 1 as per the arms they are randomized.
Participants will receive twice daily oral dose of 20 mg rabeprazole on days -3, -2, and -1.
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Area under plasma concentration-time curve from time zero to infinity (AUCinf)
Time Frame: Pre-dose, 0.25, 0.5, 0.75, 1, 1.5, 2, 3, 4, 5, 6, 8, 10, 12 hours post-dose on Day 1, and 24 hours post-dose on Day 2
|
Assessment of AUCinf for acalabrutinib and ACP-5862 (metabolite of acalabrutinib) following administration of capsule with and without rabeprazole.
|
Pre-dose, 0.25, 0.5, 0.75, 1, 1.5, 2, 3, 4, 5, 6, 8, 10, 12 hours post-dose on Day 1, and 24 hours post-dose on Day 2
|
Area under the plasma concentration-time curve from time zero to time of last quantifiable concentration (AUClast)
Time Frame: Pre-dose, 0.25, 0.5, 0.75, 1, 1.5, 2, 3, 4, 5, 6, 8, 10, 12 hours post-dose on Day 1, and 24 hours post-dose on Day 2
|
Assessment of AUClast for acalabrutinib and ACP-5862 following administration of capsule with and without rabeprazole.
|
Pre-dose, 0.25, 0.5, 0.75, 1, 1.5, 2, 3, 4, 5, 6, 8, 10, 12 hours post-dose on Day 1, and 24 hours post-dose on Day 2
|
Maximum observed plasma concentration (Cmax)
Time Frame: Pre-dose, 0.25, 0.5, 0.75, 1, 1.5, 2, 3, 4, 5, 6, 8, 10, 12 hours post-dose on Day 1, and 24 hours post-dose on Day 2
|
Assessment of Cmax for acalabrutinib and ACP-5862 following administration of capsule with and without rabeprazole.
|
Pre-dose, 0.25, 0.5, 0.75, 1, 1.5, 2, 3, 4, 5, 6, 8, 10, 12 hours post-dose on Day 1, and 24 hours post-dose on Day 2
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Number of participants with adverse events and serious adverse events
Time Frame: From screening until Follow-up visit (Upto 5 to 6 Weeks)
|
Assessment of the safety and tolerability of acalabrutinib capsule when administered with COCA-COLA and rabeprazole.
|
From screening until Follow-up visit (Upto 5 to 6 Weeks)
|
Collaborators and Investigators
Sponsor
Collaborators
Investigators
- Principal Investigator: Peter J. Winkle, MD FACP FACG CPI, Anaheim Clinical Trials
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
- D822FC00008
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
IPD Plan Description
Qualified researchers can request access to anonymized individual patient-level data from AstraZeneca group of companies sponsored clinical trials via the request portal. All requests will be evaluated as per the AZ disclosure commitment:
https://astrazenecagrouptrials.pharmacm.com/ST/Submission/Disclosure.
IPD Sharing Time Frame
IPD Sharing Access Criteria
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Infectious Disease
-
Centre de Recherche Médicale de LambarénéNot yet recruitingTropical Infectious Disease
-
Shaare Zedek Medical CenterTerminatedInfectious Disease TransmissionIsrael
-
The Third Xiangya Hospital of Central South UniversitySANSURE BIOTECH INC.UnknownInfectious Disease ScreeningChina
-
The Hong Kong Polytechnic UniversityCompletedInfectious Disease TransmissionHong Kong
-
CerbaXpertRecruiting
-
Carecubes, Inc.University of NebraskaCompletedInfectious DiseasesUnited States
-
King Saud Medical CityUnknown
-
BayerCompletedInfectious DiseasesItaly
-
Universidad de GuanajuatoAntisepsia CentralCompleted
-
LG Life SciencesCompleted
Clinical Trials on Acalabrutinib
-
AstraZenecaAcerta Pharma, LLCCompletedPharmacokinetics | BioavailabilityUnited States
-
AstraZenecaParexelCompletedCOVID-19 | Mantle Cell LymphomaGermany
-
Acerta Pharma BVAstraZenecaActive, not recruitingMantle Cell Lymphoma (MCL)United States, Poland, Italy
-
Acerta Pharma BVNational Institutes of Health (NIH)Active, not recruitingChronic Lymphocytic Leukemia | Small Lymphocytic LymphomaUnited States
-
Acerta Pharma BVAstraZenecaCompletedHepatic Insufficiency | Healthy Subjects | Hepatic ImpairmentUnited States
-
Acerta Pharma BVActive, not recruitingChronic Lymphocytic LeukemiaUnited States, United Kingdom, Belgium, Spain, Israel, France
-
AstraZenecaCompletedBioequivalenceUnited States
-
Acerta Pharma BVActive, not recruitingGlioblastoma MultiformeUnited States
-
AstraZenecaCompletedChronic Lymphocytic Leukemia and Relapsed and Refractory Mantle Cell LymphomaIndia
-
Kartos Therapeutics, Inc.RecruitingChronic Lymphocytic Leukemia | Non Hodgkin Lymphoma | Diffuse Large B Cell LymphomaBelgium, Korea, Republic of, United States, United Kingdom, Italy, Switzerland, Australia, France, Poland, Portugal, Czechia